Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine for maintenance of remission in Crohn's disease
ACTRN12612001067864Phase 4Completed
- Sponsor
- University of South Australia
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Crohn's disease and inflammatory bowel disease (IBD) comparing Fluoxetine + stable standard therapy with Placebo + stable standard therapy (2 arms). Primary endpoints: Crohn's Disease Activity Index remission/activity and World Health Organisation Quality of Life. Started Aug 2013; status: completed.
02
Drugs
fluoxetine
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on ACTRN12612001067864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001067864.